ReviewTherapeutic advances in respiratory disease2016

Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.

Omar Abdel-RahmanPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.